186 related articles for article (PubMed ID: 33430806)
1. Systemic oxidative stress and cognitive function in Parkinson's disease with different PWMH or DWMH lesions.
Chang TC; Chen YC; Huang YC; Lin WC; Lu CH
BMC Neurol; 2021 Jan; 21(1):16. PubMed ID: 33430806
[TBL] [Abstract][Full Text] [Related]
2. Classification and characterization of periventricular and deep white matter hyperintensities on MRI: A study in older adults.
Griffanti L; Jenkinson M; Suri S; Zsoldos E; Mahmood A; Filippini N; Sexton CE; Topiwala A; Allan C; Kivimäki M; Singh-Manoux A; Ebmeier KP; Mackay CE; Zamboni G
Neuroimage; 2018 Apr; 170():174-181. PubMed ID: 28315460
[TBL] [Abstract][Full Text] [Related]
3. Quantitative MRI of cerebral white matter hyperintensities: A new approach towards understanding the underlying pathology.
Iordanishvili E; Schall M; Loução R; Zimmermann M; Kotetishvili K; Shah NJ; Oros-Peusquens AM
Neuroimage; 2019 Nov; 202():116077. PubMed ID: 31398433
[TBL] [Abstract][Full Text] [Related]
4. Association between H-type Hypertension and White Matter Hyperintensity in Patients with Acute Ischemic Stroke.
Yang J; Cao Z; Jiang J; Zhou Y; Zhu X
Curr Neurovasc Res; 2023; 20(2):190-196. PubMed ID: 37221694
[TBL] [Abstract][Full Text] [Related]
5. Radiomics from magnetic resonance imaging may be used to predict the progression of white matter hyperintensities and identify associated risk factors.
Shu Z; Xu Y; Shao Y; Pang P; Gong X
Eur Radiol; 2020 Jun; 30(6):3046-3058. PubMed ID: 32086580
[TBL] [Abstract][Full Text] [Related]
6. White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.
Hanning U; Teuber A; Lang E; Trenkwalder C; Mollenhauer B; Minnerup H
Parkinsonism Relat Disord; 2019 Dec; 69():61-67. PubMed ID: 31678722
[TBL] [Abstract][Full Text] [Related]
7. Cross-sectional and longitudinal associations between total and regional white matter hyperintensity volume and cognitive and motor function in Parkinson's disease.
Pozorski V; Oh JM; Okonkwo O; Krislov S; Barzgari A; Theisen F; Sojkova J; Bendlin BB; Johnson SC; Gallagher CL
Neuroimage Clin; 2019; 23():101870. PubMed ID: 31150958
[TBL] [Abstract][Full Text] [Related]
8. Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns.
Pålhaugen L; Sudre CH; Tecelao S; Nakling A; Almdahl IS; Kalheim LF; Cardoso MJ; Johnsen SH; Rongve A; Aarsland D; Bjørnerud A; Selnes P; Fladby T
J Cereb Blood Flow Metab; 2021 May; 41(5):1162-1174. PubMed ID: 32955960
[TBL] [Abstract][Full Text] [Related]
9. Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naïve Parkinson's disease.
Jeong SH; Lee HS; Jung JH; Baik K; Sohn YH; Chung SJ; Lee PH
Parkinsonism Relat Disord; 2022 Apr; 97():1-7. PubMed ID: 35276583
[TBL] [Abstract][Full Text] [Related]
10. Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.
Crowley SJ; Banan G; Amin M; Tanner JJ; Hizel L; Nguyen P; Brumback B; Rodriguez K; McFarland N; Bowers D; Ding M; Mareci TA; Price CC
J Parkinsons Dis; 2021; 11(1):283-297. PubMed ID: 33216042
[TBL] [Abstract][Full Text] [Related]
11. Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinson's Disease.
Lee YH; Lee WJ; Chung SJ; Yoo HS; Jung JH; Baik K; Sohn YH; Seong JK; Lee PH
J Parkinsons Dis; 2021; 11(1):239-249. PubMed ID: 33074193
[TBL] [Abstract][Full Text] [Related]
12. White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease.
Mak E; Dwyer MG; Ramasamy DP; Au WL; Tan LC; Zivadinov R; Kandiah N
J Neuroimaging; 2015; 25(5):754-60. PubMed ID: 25753576
[TBL] [Abstract][Full Text] [Related]
13. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
[TBL] [Abstract][Full Text] [Related]
14. Alteration of regional homogeneity and white matter hyperintensities in amnestic mild cognitive impairment subtypes are related to cognition and CSF biomarkers.
Luo X; Jiaerken Y; Huang P; Xu XJ; Qiu T; Jia Y; Shen Z; Guan X; Zhou J; Zhang M;
Brain Imaging Behav; 2018 Feb; 12(1):188-200. PubMed ID: 28236166
[TBL] [Abstract][Full Text] [Related]
15. Cortical thinning related to periventricular and deep white matter hyperintensities.
Seo SW; Lee JM; Im K; Park JS; Kim SH; Kim ST; Ahn HJ; Chin J; Cheong HK; Weiner MW; Na DL
Neurobiol Aging; 2012 Jul; 33(7):1156-67. PubMed ID: 21316813
[TBL] [Abstract][Full Text] [Related]
16. Periventricular white matter hyperintensity burden and cognitive impairment in early Parkinson's disease.
Huang X; Wen MC; Ng SY; Hartono S; Chia NS; Choi X; Tay KY; Au WL; Chan LL; Tan EK; Tan LC
Eur J Neurol; 2020 Jun; 27(6):959-966. PubMed ID: 32124496
[TBL] [Abstract][Full Text] [Related]
17. [Value of intravoxel incoherent motion diffusion weighted imaging in evaluating the microstructure changes in white matter hyperintensities].
Yang D; Chen Y; Dong YF; Liu XL; Fu FL; Zhai LH; Xu XB; Hu SY; Zhang JJ
Zhonghua Yi Xue Za Zhi; 2019 May; 99(19):1484-1489. PubMed ID: 31137139
[No Abstract] [Full Text] [Related]
18. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.
Chahine LM; Dos Santos C; Fullard M; Scordia C; Weintraub D; Erus G; Rosenthal L; Davatzikos C; McMillan CT
Eur J Neurol; 2019 Feb; 26(2):246-e18. PubMed ID: 30169897
[TBL] [Abstract][Full Text] [Related]
19. Topography of cortical thinning associated with white matter hyperintensities in Parkinson's disease.
Ham JH; Yun HJ; Sunwoo MK; Hong JY; Lee JM; Sohn YH; Lee PH
Parkinsonism Relat Disord; 2015 Apr; 21(4):372-7. PubMed ID: 25697488
[TBL] [Abstract][Full Text] [Related]
20. White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease: results from the Ontario Neurodegenerative Diseases Research Initiative.
Carvalho de Abreu DC; Pieruccini-Faria F; Sarquis-Adamson Y; Black A; Fraser J; Van Ooteghem K; Cornish B; Grimes D; Jog M; Masellis M; Steeves T; Nanayakkara N; Ramirez J; Scott C; Holmes M; Ozzoude M; Berezuk C; Symons S; Mohammad Hassan Haddad S; Arnott SR; Binns M; Strother S; Beaton D; Sunderland K; Theyers A; Tan B; Zamyadi M; Levine B; Orange JB; Roberts AC; Lou W; Sujanthan S; Breen DP; Marras C; Kwan D; Adamo S; Peltsch A; Troyer AK; Black SE; McLaughlin PM; Lang AE; McIlroy W; Bartha R; ; Montero-Odasso M
Eur J Neurol; 2023 Apr; 30(4):920-933. PubMed ID: 36692250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
